Bruker BioSciences to Present at Bear Stearns Healthcare Conference
09 September 2005 - 6:05AM
Business Wire
Live Webcast on September 12th at 9:30 AM Eastern Time from New
York Bruker BioSciences Corporation (Nasdaq: BRKR) today announced
that it will join other leading healthcare and life sciences
companies in presenting at the Bear Stearns 18th Annual Healthcare
Conference taking place September 12 and 13 in New York. Bruker
BioSciences Corporation's Chairman, President and CEO, Frank H.
Laukien, Ph.D., will present an overview of the Company, including
an update on recent developments and expectations. He will be
accompanied by Chief Financial Officer William J. Knight. Dr.
Laukien's presentation will be webcast live at 9:30 AM Eastern Time
on Monday, September 12 from the Grand Hyatt hotel in New York. The
webcast can be accessed on Bruker BioSciences' website at
www.bruker-biosciences.com with playback available until October
12. ABOUT BRUKER BIOSCIENCES Bruker BioSciences Corporation,
headquartered in Billerica, Massachusetts, is the publicly traded
parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker
AXS is a leading developer and provider of life science and
advanced materials research tools based on X-ray technology. Bruker
Daltonics is a leading developer and provider of innovative life
science tools based on mass spectrometry. For more information,
please visit www.bruker-biosciences.com CAUTIONARY STATEMENT Any
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of
conditions, technological approaches, product development, market
acceptance, cost and pricing of the Company's products, changes in
governmental regulations, capital spending and government funding
policies, FDA and other regulatory approvals to the extent
applicable, competition, the intellectual property of others,
patent protection and litigation. These and other factors are
identified and described in more detail in our filings with the
SEC, including, without limitation, our respective annual reports
on Form 10-K for the year ended December 31, 2004 our most recent
quarterly reports on Form 10-Q, our current reports on Form 8-K and
the joint proxy statement/prospectus filed in connection with the
merger with Bruker AXS. We disclaim any intent or obligation to
update these forward-looking statements.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024